Effect of verocytotoxins (Shiga-like toxins) on human neutrophils in vitro.
Neutrophil activation occurs in diarrhoea-associated HUS and correlates with disease severity, implying a role in pathogenesis. Verocytotoxin (Shiga-like toxin) has been shown to stimulate endothelium to release chemokines and express leukocyte adhesion molecules that would lead to indirect neutrophil-endothelial interaction. A direct action of verocytotoxin (VT) on neutrophils has been proposed, although in vitro studies of this are controversial. In this report we examine the effect of verocytotoxin-1 (Shiga-like toxin-1) (VT1) and verocytotoxin-2 (VT2) on human neutrophils in vitro with regard to priming, the release of superoxide and elastase, and chemotaxis. Neutrophils were incubated with VT1 or VT2 and superoxide and elastase release was measured over 120 and 45 minutes respectively. Priming was investigated by pre-treating the neutrophils with VT1 or VT2, exposing them to formyl-met-leu-phe (fMLP) or phorbol myristic acid (PMA) and measuring superoxide release. Neutrophil chemotaxis towards fMLP was assessed with and without pre-incubation with VT1 and VT2. We found that neither of the toxins induced superoxide or elastase release. Priming with VT1 significantly reduced superoxide release when neutrophils were stimulated with fMLP or PMA. VT2 priming gave a reduced superoxide release with PMA but not fMLP. Heat-inactivation of the toxins gave similar results. Pre-treatment of neutrophils with VT1 or VT2 did not affect chemotaxis towards fMLP after a 2-hour incubation period. In conclusion, VT1 and VT2 do not activate primed neutrophils in vitro. Nor do they affect chemotaxis towards fMLP. They may impair neutrophil priming.
Holle
Julie U
JU
Department of Renal Immunobiology, The Medical School, University of Birmingham, Birmingham, B15 2TT, UK.
Williams
Julie M
JM
Harper
Lorraine
L
Savage
Caroline O S
CO
Taylor
C Mark
CM
D000818:Animals; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D002522:Chlorocebus aethiops; D006801:Humans; D018375:Neutrophil Activation / Q000187:drug effects; D009504:Neutrophils / Q000187:drug effects* / Q000502:physiology; D010196:Pancreatic Elastase / Q000096:biosynthesis; D022622:Shiga Toxin 1 / Q000494:pharmacology*; D022641:Shiga Toxin 2; D022603:Shiga Toxins / Q000494:pharmacology*; D013481:Superoxides / Q000378:metabolism; D014709:Vero Cells
D022622:Shiga Toxin 1; D022641:Shiga Toxin 2; D022603:Shiga Toxins; C430449:verocytotoxin 2; D013481:Superoxides; D010196:Pancreatic Elastase